Document is current
Any future updates will be listed below
-
Authors
Ma, Huilin https://orcid.org/0000-0003-4238-9475
Wang, Hanwen
Sové, Richard J
Wang, Jun
Giragossian, Craig
Popel, Aleksander S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02248805 at ClinicalTrials.govnct02324257 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
nct02650713 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
nct02324257 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
nct02650713 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
nct02324257 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
nct02650713 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
nct02324257 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
nct02650713 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
Documents that mention this clinical trial
Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
https://doi.org/10.1136/jitc-2020-001141
- License Information
